Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

LUME-Lung 1: BIBF 1120 Plus Docetaxel as Compared to Placebo Plus Docetaxel in 2nd Line Non Small Cell Lung Cancer

This study is ongoing, but not recruiting participants.
Information provided by (Responsible Party):
Boehringer Ingelheim Identifier:
First received: December 8, 2008
Last updated: October 7, 2014
Last verified: October 2014

The present trial will be performed to evaluate whether BIBF 1120 in combination with standard therapy of docetaxel in patients with stage IIIB/IV or recurrent NSCLC is more effective as compared to placebo in combination with standard therapy of docetaxel. A secondary aim is to obtain safety information as well as information on quality of life of patients treated with BIBF 1120 in combination to standard therapy with docetaxel. In addition, blood will be collected for pharmacokinetic analysis.

Condition Intervention Phase
Carcinoma, Non-Small-Cell Lung
Drug: placebo plus docetaxel
Drug: BIBF 1120 plus docetaxel
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Multicentre, Randomised, Double-blind, Phase III Trial to Investigate the Efficacy and Safety of Oral BIBF 1120 Plus Standard Docetaxel Therapy Compared to Placebo Plus Standard Docetaxel Therapy in Patients With Stage IIIB/IV or Recurrent Non Small Cell Lung Cancer After Failure of First Line Chemotherapy

Resource links provided by NLM:

Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • progression free survival [ Time Frame: 6 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • overall survival, [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • tumour response, [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • quality of life, [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Incidence and intensity of adverse events [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Pharmacokinetics of BIBF 1120 [ Time Frame: TBD ] [ Designated as safety issue: No ]

Estimated Enrollment: 1300
Study Start Date: December 2008
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: BIBF 1120 plus docetaxel
BIBF 1120 2 times daily along with standard therapy of docetaxel
Drug: BIBF 1120 plus docetaxel
BIBF 1120 2 times daily along with standard therapy of docetaxel
Placebo Comparator: Placebo plus docetaxel
Placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel
Drug: placebo plus docetaxel
placebo matching BIBF 1120 2 times daily along with standard therapy of docetaxel


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • male or female patient aged 18 years or older;
  • histologically or cytologically confirmed, locally advanced and/or metastatic NSCLC of stage IIIB or IV or recurrent NSCLC;
  • relapse or failure of one first line prior chemotherapy;
  • at least one target tumour lesion that has not been irradiated within the past three months and that can accurately be measured ;
  • life expectancy of at least three months;
  • ECOG score of 0 or 1;
  • patient has given written informed consent

Exclusion criteria:

  • more than one prior chemotherapy regimen for advanced and/or metastatic or recurrent NSCLC;
  • more than one chemotherapy treatment regimen (either neoadjuvant or adjuvant or neoadjuvant plus adjuvant) prior to first line chemotherapy;
  • previous therapy with other VEGFR inhibitors (other than bevacizumab) or docetaxel for treatment of NSCLC;
  • persistence of clinically relevant therapy related toxicities from previous chemotherapy and/or radiotherapy;
  • treatment with other investigational drugs or other anti-cancer therapy or treatment in another clinical trial within the past four weeks before start of - therapy or concomitantly with this trial ;
  • radiotherapy (except extremities and brain) within the past three months prior to baseline imaging;
  • active brain metastases or leptomeningeal disease;
  • radiographic evidence of cavitary or necrotic tumours;
  • centrally located tumours with radiographic evidence (CT or MRI) of local invasion of major blood vessels;
  • history of clinically significant haemoptysis within the past 3 months;
  • therapeutic anticoagulation (except low dose heparin) or antiplatelet therapy;
  • history of major thrombotic or clinically relevant major bleeding event in the past 6 months;
  • known inherited predisposition to bleeding or thrombosis;
  • significant cardiovascular diseases ;
  • inadequate safety laboratory parameters;
  • significant weight loss (> 10 %) within the past 6 weeks;
  • current peripheral neuropathy greater than CTCAE grade 2 except due to trauma;
  • preexisting ascites and/or clinically significant pleural effusion;
  • major injuries and/or surgery within the past ten days prior to randomisation with incomplete wound healing;
  • serious infections requiring systemic antibiotic therapy;
  • decompensated diabetes mellitus or other contraindication to high dose corticosteroid therapy;
  • gastrointestinal disorders or abnormalities that would interfere with absorption of the study drug;
  • active or chronic hepatitis C and/or B infection;
  • serious illness or concomitant non-oncological disease or laboratory abnormality that may increase the risk associated with study participation or study drug administration;
  • patients who are sexually active and unwilling to use a medically acceptable method of contraception during the trial and for at least twelve months after end of active therapy;
  • pregnancy or breast feeding;
  • psychological, familial, sociological or geographical factors potentially hampering compliance with the study protocol and follow-up schedule;
  • patients unable to comply with the protocol;
  • active alcohol or drug abuse;
  • other malignancy within the past three years other than basal cell skin cancer, or carcinoma in situ of the cervix;
  • any contraindications for therapy with docetaxel;
  • history of severe hypersensitivity reactions to docetaxel or other drugs formulated with polysorbate 80 (Tween 80);
  • hypersensitivity to BIBF 1120 and/or the excipients of the trial drugs;
  • hypersensitivity to contrast media
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00805194

  Show 211 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

No publications provided by Boehringer Ingelheim

Additional publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Boehringer Ingelheim Identifier: NCT00805194     History of Changes
Other Study ID Numbers: 1199.13, 2007-004803-36
Study First Received: December 8, 2008
Last Updated: October 7, 2014
Health Authority: Austria: Agency for Health and Food Safety
Belarus: Ministry of Health of Republic of Belarus
Belgium: Federal Agency for Medicinal Products and Health Products
Bulgaria: Bulgarian Drug Agency
China: SDFA
Croatia: Ministry of Health and Social Welfare of the Republic of Croatia
Czech Republic: State Institute for Drug Control
Denmark: The Danish Medicines Agency
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Georgia: Ministry of Health
Germany: Federal Institute for Drugs and Medical Devices
Great Britain: Medicines and Heathcare Products Regulatory Agency
Greece: Ministry of health & social solidarity national organization for medicines
India: Central Drug Standard Control Organization
Israel: Ministry of Health
Italy: The Italian Medicines Agency
Korea, Republic of: KFDA
Lithuania: Lithuanian Bioethics Committee
Poland: Agency for Registration of Medicinal Products, Medical Devices & Biocides
Portugal: National Pharmacy and Medicines Institute
Romania: National Medicines Agency
Russia: Federal Supervising Service for Public Health and Social Development of the Ministry of Health and Social Development of the Russian Federation
Slovakia: State Institute for Drug Control
South Africa: The Registrar, Department of Health, Medicines Control Council
Spain: Medicines and Healthcare Products Agency
Switzerland: Swissmedic
Ukraine: State Pharmacological Centre of Ministry of Health
United States: Food and Drug Administration

Additional relevant MeSH terms:
Carcinoma, Non-Small-Cell Lung
Lung Diseases
Lung Neoplasms
Bronchial Neoplasms
Carcinoma, Bronchogenic
Neoplasms by Site
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Thoracic Neoplasms
Antimitotic Agents
Antineoplastic Agents
Enzyme Inhibitors
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Therapeutic Uses
Tubulin Modulators processed this record on November 25, 2014